Immunotherapy, targeted therapy, and chemo for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining an immunotherapy drug (sintilimab) with a targeted therapy (ramucirumab) and chemotherapy (paclitaxel) for stomach cancer that came back soon after surgery and chemotherapy. The goal is to see if this combined approach can help control the cancer and prolong life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You have stomach or gastroesophageal junction cancer that has come back during or within 6 months after finishing chemotherapy after surgery
- You had a complete surgery to remove the cancer (D2 gastrectomy) with no cancer left at the edges
- Your cancer is HER2-negative (a specific protein test result)
- You have at least one tumor that can be measured on a scan
- You should be able to care for yourself and be up and about for at least half of your waking hours
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
Hear when a new Gastric Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.